e1. Graf J, Leussink VI, Dehmel T, et al. Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Ann Clin Transl Neurol. 2017;4:909–914.

e2. Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab. Rev Med Virol. 2019;29:e2077.

e3. Zanetta C, Robotti M, Nozzolillo A, et al. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature. J Neurol Sci. 2019;409:116603.

e4. Cohen BA. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology. 2019;92:435–436.

e5. Moreira Ferreira VF, Meredith D, Stankiewicz JM. Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2019;6.

e6. Roche Pharma AG. Important Information: Safety Update Ocrelizumab; 2020.

e7. Dudek MIR, Thies K, Kammenhuber S, Bösel J, Rösche J. HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab. J Neurol. 2019;266(9):2322–2323.

e8. Lattanzi S, Carlini G, Acciarri MC, Danni M, Silvestrini M. Parvovirus B19 infection in a patient with multiple sclerosis treated with ocrelizumab. Acta Neurol Belg. 2019;120 (1):231–232.

e9. Theriault M, Solomon AJ. Two cases of meningitis associated with ocrelizumab therapy. Mult Scler Relat Disord. 2019;38:101866.

e10. Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis. 2018;5:ofy174.

e11. Tallantyre EC, Whittam DH, Jolles S, et al. Secondary antibody deficiency: A complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265:1115–1122.

e12. Christou EAA, Giardino G, Worth A, Ladomenou F. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int Rev Immunol. 2017;36:352–359.

e13. Nylund M, Vuorinen T, Airas L. Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy. Mult Scler Relat Disord. 2020;42:102058.

e14. Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5:e453.

e15. Ciplea AI, Langer-Gould A, Vries A de, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7.

e16. Memon AB, Javed A, Caon C, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS ONE. 2018;13:e0190425.

e17. Abushouk AI, Ahmed H, Ismail A, et al. Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. Rheumatol Int. 2017;37:1053–1064.

e18. Conte WL, Arndt N, Cipriani VP, Dellaria A, Javed A. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2018;27:397–399.

e19. Bergman J, Burman J, Gilthorpe JD, et al. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study. Neurology. 2018;91:e1893-e1901.

e20. Pourcher V. What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. Rev Neurol (Paris). 2020;176:235–243.

e21. Förster M, Küry P, Aktas O, et al. Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Saf. 2019;42:633–647.

e22. Zappulo E, Buonomo AR, Saccà F, et al. Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. Open Forum Infect Dis. 2019;6:ofz445.

e23. Willis MD, Robertson NP. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. J Neurol. 2020;267:1567–1569.

e24. Hughes R, Pedotti R, Koendgen H. COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series. Mult Scler Relat Disord. 2020:102192.

e25. Novi G, Mikulska M, Briano F, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020;42:102120.

e26. Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185.

e27. Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020:in press.

e28. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020:102195.

e29. Sormani MP, de Rossi N; Schiavetti I, et al. Disease-modifying therapies and Covid-19 severity in Multiple Sclerosis. Ann Neurol (submitted)

e30. Valencia-Sanchez C, Wingerchuk DM. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Mult Scler Relat Disord. 2020;42:102182.

e31. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073.

e32. Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm. 2020;7.

e33. Hartung H-P, Aktas O. COVID-19 and management of neuroimmunological disorders. Nat Rev Neurol. 2020;16:347–348.

e34. Chen D, Ireland SJ, Davis LS, et al. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis. J Immunol. 2016;196:1541–1549.

e35. Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.

e36. Zheng C, Kar I, Chen CK, et al. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020;34:879–896.

e37. Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020:in press.